Amyloid-β and tau pathologies relate to distinctive brain dysconnectomics in preclinical autosomal-dominant Alzheimer's disease.
Alzheimer Disease
/ diagnostic imaging
Amyloid beta-Peptides
/ metabolism
Brain
/ diagnostic imaging
Cognitive Dysfunction
/ diagnostic imaging
Connectome
Heterozygote
Humans
Magnetic Resonance Imaging
/ methods
Memory Disorders
/ diagnostic imaging
Memory, Episodic
Positron-Emission Tomography
/ methods
Presenilin-1
/ genetics
tau Proteins
/ metabolism
fMRI
familial Alzheimer’s disease
pathology
positron emission tomography
resting-state functional connectivity
Journal
Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876
Informations de publication
Date de publication:
12 04 2022
12 04 2022
Historique:
entrez:
5
4
2022
pubmed:
6
4
2022
medline:
15
4
2022
Statut:
ppublish
Résumé
The human brain is composed of functional networks that have a modular topology, where brain regions are organized into communities that form internally dense (segregated) and externally sparse (integrated) subnetworks that underlie higher-order cognitive functioning. It is hypothesized that amyloid-β and tau pathology in preclinical Alzheimer’s disease (AD) spread through functional networks, disrupting neural communication that results in cognitive dysfunction. We used high-resolution (voxel-level) graph-based network analyses to test whether in vivo amyloid-β and tau burden was associated with the segregation and integration of brain functional connections, and episodic memory, in cognitively unimpaired Presenilin-1 E280A carriers who are expected to develop early-onset AD dementia in ∼13 y on average. Compared to noncarriers, mutation carriers exhibited less functional segregation and integration in posterior default-mode network (DMN) regions, particularly the precuneus, and in the retrospenial cortex, which has been shown to link medial temporal regions and cortical regions of the DMN. Mutation carriers also showed greater functional segregation and integration in regions connected to the salience network, including the striatum and thalamus. Greater tau burden was associated with lower segregated and integrated functional connectivity of DMN regions, particularly the precuneus and medial prefrontal cortex. In turn, greater tau pathology was related to higher segregated and integrated functional connectivity in the retrospenial cortex and the anterior cingulate cortex, a hub of the salience network. These findings enlighten our understanding of how AD-related pathology distinctly alters the brain’s functional architecture in the preclinical stage, possibly contributing to pathology propagation and ultimately resulting in dementia.
Identifiants
pubmed: 35380901
doi: 10.1073/pnas.2113641119
pmc: PMC9169643
doi:
Substances chimiques
Amyloid beta-Peptides
0
PSEN1 protein, human
0
Presenilin-1
0
tau Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2113641119Subventions
Organisme : NIA NIH HHS
ID : R01 AG061811
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG062421
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG061445
Pays : United States
Organisme : NIA NIH HHS
ID : K23 AG061276
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG010483
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL007901
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG054671
Pays : United States
Références
Brain. 2018 May 1;141(5):1517-1528
pubmed: 29538647
Neurobiol Aging. 1995 May-Jun;16(3):271-8; discussion 278-84
pubmed: 7566337
Lancet Neurol. 2011 Mar;10(3):213-20
pubmed: 21296022
Brain Connect. 2021 Apr;11(3):239-249
pubmed: 33430685
Sci Data. 2015 Jul 07;2:150031
pubmed: 26175908
Nat Med. 2018 Dec;24(12):1910-1918
pubmed: 30374196
JAMA Neurol. 2015 Aug;72(8):912-9
pubmed: 26121081
Brain. 2020 Apr 1;143(4):1233-1248
pubmed: 32252068
JAMA Neurol. 2019 Aug 01;76(8):915-924
pubmed: 31157827
Alzheimers Res Ther. 2021 Jan 15;13(1):27
pubmed: 33451357
Brain. 2018 Apr 1;141(4):1186-1200
pubmed: 29462334
Neurology. 2017 Jul 4;89(1):29-37
pubmed: 28592457
Elife. 2019 Mar 22;8:
pubmed: 30900990
Neuroimage Clin. 2017 Sep 25;17:452-464
pubmed: 29159058
JAMA Neurol. 2018 May 1;75(5):548-556
pubmed: 29435558
Nat Commun. 2020 Jan 17;11(1):347
pubmed: 31953405
Neuroimage. 2012 Feb 15;59(4):3548-62
pubmed: 22116037
JAMA Neurol. 2014 Sep;71(9):1111-22
pubmed: 25069482
Sci Rep. 2015 Jun 03;5:10532
pubmed: 26037235
J Neurosci. 2014 Jan 15;34(3):932-40
pubmed: 24431451
Neurology. 2017 Nov 14;89(20):2031-2038
pubmed: 29046362
Brain. 2018 May 1;141(5):1486-1500
pubmed: 29522171
Hum Brain Mapp. 2018 May;39(5):2020-2034
pubmed: 29363256
Hum Mutat. 1997;10(3):186-95
pubmed: 9298817
Alzheimers Dement (Amst). 2018 Jul 06;10:471-479
pubmed: 30302368
J Neurosci. 2017 Apr 19;37(16):4323-4331
pubmed: 28314821
J Neuropathol Exp Neurol. 2011 Nov;70(11):960-9
pubmed: 22002422
Acta Neuropathol. 2018 Jul;136(1):57-67
pubmed: 29752551
Hum Brain Mapp. 2018 Dec;39(12):4663-4677
pubmed: 30004604
Alzheimers Dement. 2017 Nov;13(11):1261-1269
pubmed: 28366797
Nat Commun. 2020 May 26;11(1):2612
pubmed: 32457389
Nat Commun. 2019 Oct 25;10(1):4900
pubmed: 31653847
Brain. 2019 Apr 1;142(4):1093-1107
pubmed: 30770704
Neurology. 2013 Aug 20;81(8):736-44
pubmed: 23884042
Rev Neurol. 2007 Dec 1-15;45(11):655-60
pubmed: 18050096
Biol Psychiatry. 2020 May 1;87(9):808-818
pubmed: 31735253
J Neurophysiol. 2011 Sep;106(3):1125-65
pubmed: 21653723
Alzheimers Dement. 2011 May;7(3):280-92
pubmed: 21514248
Cell Rep. 2015 May 26;11(8):1176-83
pubmed: 25981034
J Alzheimers Dis. 2018;61(1):265-281
pubmed: 29154274